Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronidazole in postgastrectomy syndrome
NCT01658852Phase 3Withdrawn
- Sponsor
- The Catholic University of Korea
- Start
- May 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in small intestinal bacterial overgrowth (SIBO) comparing Metronidazole with Placebo (2 arms). Primary endpoint: Patient's Global Assessment of abdominal symptom at 4 weeks. Planned start May 2011; status: withdrawn.
02
Drugs
metronidazole
03
Conditions
small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT01658852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658852.